FDA delays camizestrant breast cancer drug decision after ODAC vote against benefit-risk profile on May 27, 2026 AstraZeneca camizestrant CDK4/6 inhibitor decision delay ESR1 gene Malignant neoplasm of breast Mutation negative adcomm ODAC Oncologic Phase III United States Food and Drug Administration +